Evaluation Multi-Cancer Early Detection Tests: Novel Strategies to Improve Cancer Screening in Primary Care Practice Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). Did this activity meet your educational needs? Yes No Did this activity increase your competence? Yes No Do you feel like there were any new data presented during this activity? Yes - please explain: No Did you learn anything new? Yes, please specify: No Did you gain confidence in your ability to act on the new information? Yes - please explain: No Did this activity include opportunities to learn as a part of a healthcare team? Yes - please explain: No Please answer the following question using a 5-point likert scale (5 = a great deal, 3 = a modest amount, 1 = nothing at all). How much did you learn as a result of this session? 5 4 3 2 1 Please rate the following components related to this activity using a 5-point likert scale (5 = excellent, 3 = good, 1 = poor). Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Overall 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Dr. Mylynda Massart 5 4 3 2 1 To what extent were the following learning objectives addressed by this activity (5 = entirely, 3 = moderately, 1 = not at all)? Describe current barriers to cancer screening, including limitations of cancer screening guidelines, health and sociodemographic disparities, and patient engagement challenges 5 4 3 2 1 Review the latest advances in cancer biology and the subsequent development of early cancer detection screening tests 5 4 3 2 1 Evaluate and differentiate between available and emerging blood-based MCED tests for cancer screening and early cancer detection 5 4 3 2 1 Assess strategies to improve the clinical integration and workflow optimization of MCED tests in primary care practice for the early identification, diagnosis, and timely referral of cancer 5 4 3 2 1 The information presented in this activity was free of commercial bias. Agree Disagree How many patients who are candidates for MCED screening do you encounter on a monthly basis? 10 or fewer 20 30 40 50 or more Based on my participation in this activity, I anticipate I will more often: (select all that apply) Implement MCED tests into clinical practice Review/update protocols related to cancer screening/early cancer detection Consider the limitations of current cancer screening guidelines Assess the health and sociodemographic disparities that impact cancer screening Evaluate patient engagement challenges in cancer screening Review the latest advances in cancer biology and the subsequent development of MCED tests Evaluate and differentiate between available and emerging blood-based MCED tests for cancer screening and early cancer detection Remain apprised of promising clinical data associated with MCED tests for improved cancer-related detection and outcomes Consider strategies to improve the clinical integration and workflow optimization of MCED tests in routine practice Other (please specify): Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No Which of the following barriers do you perceive in your efforts to implement practice changes and/or optimize patient care? Select all that apply. No barriers Cost Lack of opportunity/patients Lack of administrative support Insurance/reimbursement issues Lack of consensus or professional guidelines Lack of time to assess/counsel patients Patient compliance issues Not applicable to my practice Other: How might future activities help you address those barriers? 255 characters max Which of the following statements regarding cancer screening is TRUE? A. 14% of all US cancers are detected by preventive screening tests B. 65% of Americans 21 years and older are up to date on all recommended cancer screening tests C. 75% of the cancers in the US that cause fatalities are screened for regularly D. The ACS recommends routine cancer screening for nine types of cancer The Circulating Cell-Free Genome Atlas Study (CCGA) study, designed to depict the landscape of genomic cancer signals in the blood of persons with and without cancer, highlighted the potential of ______ in multi-cancer detection testing. A. Chromosomal mutations B. DNA methylation C. Genetic mutations D. Tumor suppressor genes Which of the following is a commercially available MCED test that is able to detect >50 cancers through a single blood draw? A. Burning Rock B. CancerSEEK C. Galleri D. PanSeer How interested are you now in exploring areas related to early cancer detection and/or MCED testing? A. Very interested B. Interested C. Somewhat interested D. Not very interested E. Not at all interested How confident are you now in your ability to discuss MCED testing with patients? A. Very confident B. Confident C. Somewhat confident D. Not very confident E. Not at all confident How often do you now consider MCED tests in clinical practice for the early detection of cancer? Always Often Sometimes Rarely Never How confident are you now in your ability to improve the clinical integration and workflow optimization of MCED tests in routine practice? Very confident Confident Somewhat confident Not very confident Not at all confident Previous
